Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-05-01
2010-12-14
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S197110, C424S236100, C424S247100, C424S250100, C424S182100, C424S682000, C424S698000, C424S278100, C424S282100, C424S283100
Reexamination Certificate
active
07850973
ABSTRACT:
The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.
REFERENCES:
patent: 6743427 (2004-06-01), Schenk
patent: 6787144 (2004-09-01), Schenk
patent: 6808712 (2004-10-01), Schenk
patent: 2003/0157117 (2003-08-01), Rasmussen et al.
patent: 2005/0053575 (2005-03-01), Solomon
patent: 2007/0134762 (2007-06-01), Arumugham et al.
patent: WO 00/72880 (2000-12-01), None
patent: 2004069182 (2004-08-01), None
Cribbs, et al., “Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with Beta-amyloid,” International Immunology, vol. 15, No. 4, 2003, pp. 505-514.
Agadjanyan, et al., “Prototype Alzheimer's Disease Vaccine Using the Immunodominant B Cell Epitope from Beta-Amyloid Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide,” Journal of Immunology, vol. 174, No. 3, 2005, pp. 1580-1586.
Bacskai, et al., Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-B in Vivo by Immunotherapy,: The Journal of Neuroscience, Sep. 15, 2002, vol. 22, No. 18, pp. 7873-7878.
Bard, et al., “Peripherally administered antibodies against amyloid B-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,” Nature Medicine, vol. 6, No. 8, Aug. 2000, pp. 916-919.
Davis, et al., “Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double AB in human ABPP transgenic mice,” Neurobiology of Aging, vol. 27, 2006, pp. 946-954.
Deane, et al., “AgG—Assisted Age-Dependent Clearance of Alzheimer's Amyloid B Peptide by the Blood-Brain Barrier Neonatal Fc Receptor”, The Journal of Neuroscience, Dec. 14, 2005, vol. 25, No. 50, pp. 11495-11503.
DeMattos, et al., “Peripheral anti-AB antibody alters CNS and plasma AB clearance and decreases brain AB burden in a mouse model of Alzheimer's disease,” PNAS, vol. 98, No. 15, Jul. 17, 2001, pp. 8850-8555.
Ferrer, et al., “Neuropathology and Pathogenesis of Encephalitis Following Amyloid-B Immunization in Alzheimer's Disease,” Brain Pathology, vol., 14, 2004, pp. 11-20.
Gilman, et al., “Clinical effects of AB immunization (AN1792) in patients with AD in an interrupted trial,” Neurology, vol. 64, May 2005, pp. 1553-1562.
Janus, et al., “AB peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease,” Letters to Nature, vol. 408, Dec. 2000, pp. 979-982.
Lee, et al., “AB immunization: Moving AB peptide from brain to blood,” PNAS, Jul. 31, 2001, vol. 98, No. 16, pp. 8931-8932.
Mesliah, et al., “AB vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease,” Neurology, vol. 64, Jan. 2005, pp. 129-131.
Monsonego, et al., “Increased T cell reactivity to amyloid B protein in older humans and patients with Alzheimer disease,” J. Journal of Clinical Investigation, Aug. 2003, vol. 112, No. 3, pp. 415-422.
Morgan, et al., AB peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, vol. 48, Dec. 2000, pp. 982-985.
Nicoll, et al., “Neuropathology of human Alzheimer disease after immunization with amyloid-B peptide: a case report,” Nature Medicine, vol. 9, No. 4, Apr. 2003, pp. 448-452.
Orgogozo, et al., “Subacute meningoencephalitis in a subset of patients with AD after AB42 immunization,” Neurology, vol. 61, Jul. 2003, pp. 46-54.
Schenk, et al., “Immunization with amyloid-B attenuates Alzheimer-diesase-like pathology in the PDAPP mouse,” Letters to Nature, vol. 400, Jul. 8, 199, pp. 173-177.
Senior, “Drug with potential to clear amyloid,” The Lancet Neurology, vol. 1, Jul. 2002, p. 142.
Wilcock, et al., “Intracranially Administered Anti-AB Antibodies Reduce B-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation,” Journal of Neuroscience, vol. 23, No. 9, 2003, pp. 3745-3751.
Garsky Victor M.
Joyce Joseph G.
Keller Paul M.
Kinney Gene
Liang Xiaoping
Ballard Kimberly A.
Devlin Gerard
Kolker Daniel E
Merck Sharp & Dohme Corp.
Switzer Joan E.
LandOfFree
Peptide conjugate compositions and methods for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide conjugate compositions and methods for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide conjugate compositions and methods for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4225785